- Home
- KIND vs QURE Comparison
KIND vs QURE Comparison
Compare KIND & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIND
- QURE
- Stock Information
- Founded
- KIND 2011
- QURE 1998
- Country
- KIND United States
- QURE Netherlands
- Employees
- KIND N/A
- QURE N/A
- Industry
- KIND Computer Software: Programming Data Processing
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- KIND Technology
- QURE Health Care
- Exchange
- KIND Nasdaq
- QURE Nasdaq
- Market Cap
- KIND 974.5M
- QURE 860.8M
- IPO Year
- KIND N/A
- QURE 2007
- Fundamental
- Price
- KIND $2.42
- QURE $14.86
- Analyst Decision
- KIND Hold
- QURE Strong Buy
- Analyst Count
- KIND 2
- QURE 8
- Target Price
- KIND $2.75
- QURE $33.00
- AVG Volume (30 Days)
- KIND 1.3M
- QURE 1.2M
- Earning Date
- KIND 02-25-2025
- QURE 02-26-2025
- Dividend Yield
- KIND N/A
- QURE N/A
- EPS Growth
- KIND N/A
- QURE N/A
- EPS
- KIND N/A
- QURE N/A
- Revenue
- KIND $237,605,000.00
- QURE $28,587,000.00
- Revenue This Year
- KIND $14.90
- QURE $153.92
- Revenue Next Year
- KIND $14.38
- QURE N/A
- P/E Ratio
- KIND N/A
- QURE N/A
- Revenue Growth
- KIND 9.99
- QURE N/A
- 52 Week Low
- KIND $1.52
- QURE $3.73
- 52 Week High
- KIND $3.00
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- KIND 48.47
- QURE 52.73
- Support Level
- KIND $2.38
- QURE $13.70
- Resistance Level
- KIND $2.48
- QURE $15.18
- Average True Range (ATR)
- KIND 0.07
- QURE 1.07
- MACD
- KIND 0.01
- QURE -0.54
- Stochastic Oscillator
- KIND 59.57
- QURE 29.76
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.